Pharvaris N.V. (PHVS)

$29.36 +5.24 (21.75%)
Market Cap 1.26B
Revenue (ttm) 0.00
Net Income (ttm) -145.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,541,600
Avg Vol 339,888
Day's Range N/A - N/A
Shares Out 52.29M
Stochastic %K 95%
Beta -2.80
Analysts Strong Sell
Price Target $38.60

Company Profile

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 tria...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 712036410
Address:
Grafenauweg 8, Zug, Switzerland
BearTamerTrading
BearTamerTrading Dec. 4 at 2:30 AM
📈 Market Alerts — Bear Tamer Trading 🔥 $KITT — Robotics/automation name with strong intraday momentum and steady higher-lows reclaim. 🔥 $MCRP — Micro-cap runner showing sharp volatility and heavy liquidity rotations during market hours. 🔥 $AHMA — Recent low-float mover with controlled intraday trend and consistent grind. 🔥 $IRBT — Robotics sector name attracting volume from headline attention + intraday range strength. 🔥 $PHVS — Pharma/biotech name with solid liquidity and clean intraday push structure. Congrats to everyone who caught these live on Market Alerts today 💰👏 Here’s the proof we alerted all of them live ⬇️ 🔗 https://www.youtube.com/live/glMYt0HMYn0?si=7S_Ahf2_zcaXnG2b Stay tuned, the momentum doesn’t stop. 🚀
0 · Reply
WycklyTrader
WycklyTrader Dec. 3 at 11:10 PM
$PHVS 52wk high (re-accumulation) on positive phase3 data with expected PDUFA catalyst. QNCX 52wk high base breakout momentum with phase3 data due 1Q2026. $IBB $XLV $SPY $QQQ :..
0 · Reply
Sw1ngb0t
Sw1ngb0t Dec. 3 at 10:28 PM
$PHVS $CCCC $GOSS $ERAS some newbs
0 · Reply
prismmarketview
prismmarketview Dec. 3 at 8:12 PM
Pharvaris (Nasdaq: $PHVS) reported strong Phase 3 data for deucrictibant, showing rapid symptom relief and a clean safety profile in HAE attacks. The results support its upcoming 2026 NDA for on-demand treatment. https://prismmarketview.com/pharvaris-reports-strong-phase-3-results-supporting-deucrictibant-for-on-demand-hae-treatment/
0 · Reply
JarvisFlow
JarvisFlow Dec. 3 at 7:14 PM
HC Wainwright & Co. has adjusted their stance on Pharvaris ( $PHVS ), setting the rating to Buy with a target price of 60.
0 · Reply
Profitrip
Profitrip Dec. 3 at 3:34 PM
$ARWR $SMX $BOX $PHVS on my breakout scan!
0 · Reply
TaxWriteOffsPls
TaxWriteOffsPls Dec. 3 at 3:07 PM
$PHVS Great data, they blow KALV out of the water and this reinforces future extended-release readout. I think it will run up eventually before Chapter-3 which is hopefully going to be a chance to trim position
0 · Reply
JFais
JFais Dec. 3 at 2:51 PM
$KALV (L) Verdict on my position post $PHVS phase 3 data (done well in it so far since entry at October lows)
1 · Reply
JFais
JFais Dec. 3 at 2:48 PM
Both $KALV & $PHVS up on the latter's idea- an unexpected outcome
0 · Reply
Silky007
Silky007 Dec. 3 at 2:27 PM
$PHVS 3 minutes
0 · Reply
Latest News on PHVS
Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript

Dec 3, 2025, 5:43 PM EST - 4 hours ago

Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript

Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows

Dec 3, 2025, 10:09 AM EST - 11 hours ago

Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows

Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks

Dec 3, 2025, 6:50 AM EST - 15 hours ago

Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks

A $68 Million Signal: What General Atlantic Sees in Pharvaris Right Now

Dec 2, 2025, 10:58 PM EST - 23 hours ago

A $68 Million Signal: What General Atlantic Sees in Pharvaris Right Now

Pharvaris: Biotech With De-Risked Phase 3 Readout Coming, Initiating With A Buy Rating

Nov 23, 2025, 5:36 AM EST - 10 days ago

Pharvaris: Biotech With De-Risked Phase 3 Readout Coming, Initiating With A Buy Rating

Why Bain Capital Is Selling Shares of This Biotech Stock Now

Nov 18, 2025, 1:03 PM EST - 15 days ago

Why Bain Capital Is Selling Shares of This Biotech Stock Now

Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 6:50 AM EST - 21 days ago

Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update

Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting

Nov 10, 2025, 6:50 AM EST - 23 days ago

Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting

Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting

Oct 23, 2025, 6:50 AM EDT - 5 weeks ago

Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting

Pharvaris N.V. (PHVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 1:07 PM EDT - 3 months ago

Pharvaris N.V. (PHVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Pharvaris N.V. (PHVS) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 5, 2025, 1:04 AM EDT - 3 months ago

Pharvaris N.V. (PHVS) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Pharvaris N.V. (PHVS) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 4, 2025, 5:25 AM EDT - 3 months ago

Pharvaris N.V. (PHVS) Presents At Cantor Global Healthcare Conference 2025 Transcript

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 12, 2025, 4:05 PM EDT - 4 months ago

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

Pharvaris: Deucrictibant Advanced To Target Two Sets Of HAE Patient Populations

Jul 23, 2025, 3:15 PM EDT - 4 months ago

Pharvaris: Deucrictibant Advanced To Target Two Sets Of HAE Patient Populations

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Jul 22, 2025, 9:22 PM EDT - 4 months ago

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Pharvaris Announces Proposed Public Offering of Ordinary Shares

Jul 22, 2025, 4:05 PM EDT - 4 months ago

Pharvaris Announces Proposed Public Offering of Ordinary Shares

Pharvaris: More Convenience, More Potency, And More Potential For Future HAE Success

Jul 18, 2025, 4:41 AM EDT - 4 months ago

Pharvaris: More Convenience, More Potency, And More Potential For Future HAE Success

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

Jul 10, 2025, 6:50 AM EDT - 5 months ago

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

Jun 27, 2025, 6:50 AM EDT - 5 months ago

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

Jun 16, 2025, 6:50 AM EDT - 6 months ago

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

Pharvaris Announces Annual Meeting of Shareholders

Jun 10, 2025, 6:50 AM EDT - 6 months ago

Pharvaris Announces Annual Meeting of Shareholders

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

Jun 2, 2025, 6:50 AM EDT - 6 months ago

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

May 19, 2025, 6:50 AM EDT - 7 months ago

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:05 PM EDT - 7 months ago

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4

May 12, 2025, 6:50 AM EDT - 7 months ago

Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Apr 7, 2025, 6:58 AM EDT - 8 months ago

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

Apr 1, 2025, 6:50 AM EDT - 8 months ago

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

Mar 3, 2025, 6:50 AM EST - 9 months ago

Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

Mar 3, 2025, 6:48 AM EST - 9 months ago

Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

Pharvaris Outlines 2025 Strategic Priorities

Jan 13, 2025, 6:50 AM EST - 11 months ago

Pharvaris Outlines 2025 Strategic Priorities

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Nov 13, 2024, 4:10 PM EST - 1 year ago

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference

Nov 12, 2024, 6:50 AM EST - 1 year ago

Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

Oct 16, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

Pharvaris to Host Virtual Investor Event on October 23, 2024

Oct 15, 2024, 6:50 AM EDT - 1 year ago

Pharvaris to Host Virtual Investor Event on October 23, 2024

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop

Oct 3, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop

Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

Sep 5, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024

Sep 5, 2024, 6:49 AM EDT - 1 year ago

Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024

Pharvaris Presents Data at the Bradykinin Symposium 2024

Sep 5, 2024, 6:48 AM EDT - 1 year ago

Pharvaris Presents Data at the Bradykinin Symposium 2024

Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium

Aug 28, 2024, 6:50 AM EDT - 1 year ago

Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium

Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

Jun 4, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses

May 13, 2024, 6:50 AM EDT - 1 year ago

Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses

Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024, 4:10 PM EDT - 1 year ago

Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Apr 10, 2024, 4:10 PM EDT - 1 year ago

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

Apr 10, 2024, 4:08 PM EDT - 1 year ago

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

Apr 4, 2024, 6:50 AM EDT - 1 year ago

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

Mar 18, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

Mar 6, 2024, 6:50 AM EST - 1 year ago

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

Pharvaris to Participate in the Leerink Global Biopharma Conference 2024

Mar 5, 2024, 6:50 AM EST - 1 year ago

Pharvaris to Participate in the Leerink Global Biopharma Conference 2024

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

Feb 22, 2024, 6:50 AM EST - 1 year ago

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

BearTamerTrading
BearTamerTrading Dec. 4 at 2:30 AM
📈 Market Alerts — Bear Tamer Trading 🔥 $KITT — Robotics/automation name with strong intraday momentum and steady higher-lows reclaim. 🔥 $MCRP — Micro-cap runner showing sharp volatility and heavy liquidity rotations during market hours. 🔥 $AHMA — Recent low-float mover with controlled intraday trend and consistent grind. 🔥 $IRBT — Robotics sector name attracting volume from headline attention + intraday range strength. 🔥 $PHVS — Pharma/biotech name with solid liquidity and clean intraday push structure. Congrats to everyone who caught these live on Market Alerts today 💰👏 Here’s the proof we alerted all of them live ⬇️ 🔗 https://www.youtube.com/live/glMYt0HMYn0?si=7S_Ahf2_zcaXnG2b Stay tuned, the momentum doesn’t stop. 🚀
0 · Reply
WycklyTrader
WycklyTrader Dec. 3 at 11:10 PM
$PHVS 52wk high (re-accumulation) on positive phase3 data with expected PDUFA catalyst. QNCX 52wk high base breakout momentum with phase3 data due 1Q2026. $IBB $XLV $SPY $QQQ :..
0 · Reply
Sw1ngb0t
Sw1ngb0t Dec. 3 at 10:28 PM
$PHVS $CCCC $GOSS $ERAS some newbs
0 · Reply
prismmarketview
prismmarketview Dec. 3 at 8:12 PM
Pharvaris (Nasdaq: $PHVS) reported strong Phase 3 data for deucrictibant, showing rapid symptom relief and a clean safety profile in HAE attacks. The results support its upcoming 2026 NDA for on-demand treatment. https://prismmarketview.com/pharvaris-reports-strong-phase-3-results-supporting-deucrictibant-for-on-demand-hae-treatment/
0 · Reply
JarvisFlow
JarvisFlow Dec. 3 at 7:14 PM
HC Wainwright & Co. has adjusted their stance on Pharvaris ( $PHVS ), setting the rating to Buy with a target price of 60.
0 · Reply
Profitrip
Profitrip Dec. 3 at 3:34 PM
$ARWR $SMX $BOX $PHVS on my breakout scan!
0 · Reply
TaxWriteOffsPls
TaxWriteOffsPls Dec. 3 at 3:07 PM
$PHVS Great data, they blow KALV out of the water and this reinforces future extended-release readout. I think it will run up eventually before Chapter-3 which is hopefully going to be a chance to trim position
0 · Reply
JFais
JFais Dec. 3 at 2:51 PM
$KALV (L) Verdict on my position post $PHVS phase 3 data (done well in it so far since entry at October lows)
1 · Reply
JFais
JFais Dec. 3 at 2:48 PM
Both $KALV & $PHVS up on the latter's idea- an unexpected outcome
0 · Reply
Silky007
Silky007 Dec. 3 at 2:27 PM
$PHVS 3 minutes
0 · Reply
theflynews
theflynews Dec. 3 at 2:08 PM
Morning Movers: Macy's dips following third quarter earnings report - $PHVS - https://thefly.com/permalinks/entry.php/PHVSid4249365?1764770
0 · Reply
TheDizPlinTrader
TheDizPlinTrader Dec. 3 at 1:56 PM
$PHVS 💊 1 Hour Levels Price: $26.99 Support: $25.80 Resistance: $28.40
0 · Reply
mikesterz7
mikesterz7 Dec. 3 at 1:48 PM
$PHVS The RAPIDe-3 Phase 3 study is Pharvaris’ first trial for on-demand treatment of HAE attacks.
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 3 at 1:34 PM
$PHVS (+6.8% pre) Pharvaris stock surges after positive HAE treatment study results https://ooc.bz/l/86087
0 · Reply
topstockalerts
topstockalerts Dec. 3 at 1:26 PM
$PHVS waking up.. 🏦
0 · Reply
StocktwitsNews
StocktwitsNews Dec. 3 at 1:15 PM
PHVS Stock Jumps After Phase 3 Trial Shows Rapid Symptom Relief For Oral HAE Treatment $PHVS https://stocktwits.com/news/equity/markets/phvs-stock-jumps-after-phase3-trial-for-oral-hae-treatment/cLIXqvvRE1J
0 · Reply
topstockalerts
topstockalerts Dec. 3 at 1:01 PM
Pre Market Top Gainers $KXIN $PMAX $DTSQU $CMCT $PHVS
0 · Reply
Stock_Catcher
Stock_Catcher Dec. 3 at 12:48 PM
$PHVS Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks
0 · Reply
topstockalerts
topstockalerts Dec. 3 at 12:47 PM
Pre Market Top Gainers PT2 $PHVS $MVLL $ALZN $NXXT $GSUN
0 · Reply
Disrupter
Disrupter Dec. 3 at 12:44 PM
$PHVS no volume yet, but it can be a good thing
0 · Reply
2HandedStroker
2HandedStroker Dec. 3 at 12:38 PM
$PHVS Jumped waaay up in early PreMkt but has turned horizontal last 30 minutes
0 · Reply
charles39wilson
charles39wilson Dec. 3 at 12:31 PM
Christmas rally will happen this month! $GME $PHVS $AEO $BGM $COIN
0 · Reply